BUZZ-Oppenheimer starts Aardvark with 'outperform' on differentiated obesity franchise

Reuters2025-12-23

BUZZ-Oppenheimer starts Aardvark with 'outperform' on differentiated obesity franchise

** Brokerage Oppenheimer initiates coverage on Aardvark Therapeutics AARD.O with an "outperform" rating and a $35 PT, which implies a more than twofold upside to stock's last close

** AARD can build a strong business in both Prader-Willi syndrome $(PWS)$ and common obesity, and upcoming data next year and beyond can move the stock higher - brokerage

** PWS is a rare genetic condition that affects how a child grows, leading to weak muscles, short height and learning difficulties

** Oppenheimer sees the upcoming late-stage readout of AARD's experimental drug ARD-101 for treating PWS as a major catalyst and believes it potentially offers better safety compared to Soleno Therapeutics' SLNO.O FDA approved drug Vykat XR

** Oppenheimer says AARD's experimental oral drug for obesity ARD-201 could slot into obesity care on several fronts if human data confirm preclinical results

** ARD-201 could offer an alternative for patients unwilling or unable to use injectable GLP-1 therapies, and act as a maintenance option to help prevent weight regain after patients stop GLP-1 injections due to side-effects or other issues, brokerage says

** As of last close, AARD stock down 9% since its February Nasdaq debut

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593497970?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-23 20:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593497970","market":"nz","top_or_hot":-1,"title":"BUZZ-Oppenheimer starts Aardvark with 'outperform' on differentiated obesity franchise","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Oppenheimer starts Aardvark with 'outperform' on differentiated obesity franchise</title></head><body><p>** Brokerage Oppenheimer initiates coverage on <a href=\"https://laohu8.com/S/AARD\">Aardvark Therapeutics</a> <span>AARD.O</span> with an \"outperform\" rating and a $35 PT, which implies a more than twofold upside to stock's last close</p><p>** AARD can build a strong business in both Prader-Willi syndrome <a href=\"https://laohu8.com/S/PWS\">$(PWS)$</a> and common obesity, and upcoming data next year and beyond can move the stock higher - brokerage</p><p>** PWS is a rare genetic condition that affects how a child grows, leading to weak muscles, short height and learning difficulties</p><p>** Oppenheimer sees the upcoming late-stage readout of AARD's experimental drug ARD-101 for treating PWS as a major catalyst and believes it potentially offers better safety compared to <a href=\"https://laohu8.com/S/SLNO\">Soleno Therapeutics</a>' <span>SLNO.O</span> FDA approved drug Vykat XR</p><p>** Oppenheimer says AARD's experimental oral drug for obesity ARD-201 could slot into obesity care on several fronts if human data confirm preclinical results</p><p>** ARD-201 could offer an alternative for patients unwilling or unable to use injectable GLP-1 therapies, and act as a maintenance option to help prevent weight regain after patients stop GLP-1 injections due to side-effects or other issues, brokerage says</p><p>** As of last close, AARD stock down 9% since its February Nasdaq debut </p><p>(Reporting by Padmanabhan Ananthan)</p><p>((Padmanabhan.Ananthan@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Oppenheimer starts Aardvark with 'outperform' on differentiated obesity franchise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Oppenheimer starts Aardvark with 'outperform' on differentiated obesity franchise\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-23 20:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Oppenheimer starts Aardvark with 'outperform' on differentiated obesity franchise</title></head><body><p>** Brokerage Oppenheimer initiates coverage on <a href=\"https://laohu8.com/S/AARD\">Aardvark Therapeutics</a> <span>AARD.O</span> with an \"outperform\" rating and a $35 PT, which implies a more than twofold upside to stock's last close</p><p>** AARD can build a strong business in both Prader-Willi syndrome <a href=\"https://laohu8.com/S/PWS\">$(PWS)$</a> and common obesity, and upcoming data next year and beyond can move the stock higher - brokerage</p><p>** PWS is a rare genetic condition that affects how a child grows, leading to weak muscles, short height and learning difficulties</p><p>** Oppenheimer sees the upcoming late-stage readout of AARD's experimental drug ARD-101 for treating PWS as a major catalyst and believes it potentially offers better safety compared to <a href=\"https://laohu8.com/S/SLNO\">Soleno Therapeutics</a>' <span>SLNO.O</span> FDA approved drug Vykat XR</p><p>** Oppenheimer says AARD's experimental oral drug for obesity ARD-201 could slot into obesity care on several fronts if human data confirm preclinical results</p><p>** ARD-201 could offer an alternative for patients unwilling or unable to use injectable GLP-1 therapies, and act as a maintenance option to help prevent weight regain after patients stop GLP-1 injections due to side-effects or other issues, brokerage says</p><p>** As of last close, AARD stock down 9% since its February Nasdaq debut </p><p>(Reporting by Padmanabhan Ananthan)</p><p>((Padmanabhan.Ananthan@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AARD","symbol_name":"Aardvark Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nL6N3XT0JS:1","article_id":"2593497970","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593497970","pubTimestamp":1766492737,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Oppenheimer starts Aardvarkwith 'outperform' on differentiated obesity franchise** Brokerage Oppenheimer initiates coverage on Aardvark Therapeutics AARD.O with an \"outperform\" rating and a $35 P","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AARD":"Aardvark Therapeutics","SLNO":"Soleno Therapeutics","BK4139":"生物科技"},"translate_title":"巴兹-奥本海默(BUZZ-Oppenheimer)以“跑赢大盘”的差异化肥胖特许经营权启动Aardvark","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AARD":0.9,"SLNO":0.9},"content_text":"BUZZ-Oppenheimer starts Aardvark with 'outperform' on differentiated obesity franchise** Brokerage Oppenheimer initiates coverage on Aardvark Therapeutics AARD.O with an \"outperform\" rating and a $35 PT, which implies a more than twofold upside to stock's last close** AARD can build a strong business in both Prader-Willi syndrome $(PWS)$ and common obesity, and upcoming data next year and beyond can move the stock higher - brokerage** PWS is a rare genetic condition that affects how a child grows, leading to weak muscles, short height and learning difficulties** Oppenheimer sees the upcoming late-stage readout of AARD's experimental drug ARD-101 for treating PWS as a major catalyst and believes it potentially offers better safety compared to Soleno Therapeutics' SLNO.O FDA approved drug Vykat XR** Oppenheimer says AARD's experimental oral drug for obesity ARD-201 could slot into obesity care on several fronts if human data confirm preclinical results** ARD-201 could offer an alternative for patients unwilling or unable to use injectable GLP-1 therapies, and act as a maintenance option to help prevent weight regain after patients stop GLP-1 injections due to side-effects or other issues, brokerage says** As of last close, AARD stock down 9% since its February Nasdaq debut (Reporting by Padmanabhan Ananthan)((Padmanabhan.Ananthan@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593497970","isCrawlerRequest":true}